Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Seems Ready For Return Of Zelnorm, But Seeks Advice On Best Subpopulation

Oct 17 2018

• By Michael Cipriano

Risk Dial

Related Content

US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

Sep 17 2018

Shire’s Prucalopride Brings Real-World CV Safety Data To US FDA Panel, But Will It Be Enough?

Oct 16 2018

Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says

Apr 02 2007

FDA May Ease Up On CV Safety Requirements For GI Motility Drugs Compared To Diabetes, Obesity

Dec 05 2011

Related Companies

Novartis AG

US WorldMeds, LLC

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States Advisory Committees Drug Review Regulation Gastrointestinal BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window